Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00381641 · ClinicalTrials.gov registry record · Phase 2
Sunitinib Malate in Treating Patients With Thyroid Cancer That Did Not Respond to Iodine I 131 and Cannot Be Removed by Surgery
A Phase 2 study of Recurrent Thyroid Gland Carcinoma and Refractory Thyroid Gland Carcinoma, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 63
- Enrollment target
- 17
- Study locations
NCT00381641 is a Phase 2 study of Recurrent Thyroid Gland Carcinoma and Refractory Thyroid Gland Carcinoma that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 63 participants, above the 35-participant average among 3 other Recurrent Thyroid Gland Carcinoma trials with a reported enrollment target (80% higher). The trial reports 17 study locations across 7 states.
The verdict
NCT00381641, a Phase 2 study of Recurrent Thyroid Gland Carcinoma and Refractory Thyroid Gland Carcinoma, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 63 participants
- Enrollment target
- 17
- Study locations
Study Summary
This phase II trial studies how well sunitinib malate works in treating patients with thyroid cancer that did not respond to iodine I 131 (radioactive iodine) and cannot be removed by surgery. Sunitinib malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
Conditions Studied
Interventions
- OTHER Laboratory Biomarker Analysis
- DRUG Sunitinib
- OTHER Pharmacogenomic Study
- DRUG Sunitinib Malate
Study Locations (17)
Illinois
- University of Chicago Comprehensive Cancer Center - Chicago
- Decatur Memorial Hospital - Decatur
- NorthShore University HealthSystem-Evanston Hospital - Evanston
- Ingalls Memorial Hospital - Harvey
- Duly Health and Care Joliet - Joliet
- Loyola University Medical Center - Maywood
- Illinois CancerCare-Peoria - Peoria
- Central Illinois Hematology Oncology Center - Springfield
- Southern Illinois University School of Medicine - Springfield
Indiana
- Fort Wayne Medical Oncology and Hematology Inc-Parkview - Fort Wayne
- Northern Indiana Cancer Research Consortium - South Bend
Michigan
- University of Michigan Comprehensive Cancer Center - Ann Arbor
- Oncology Care Associates PLLC - Saint Joseph
Maryland
- University of Maryland/Greenebaum Cancer Center - Baltimore
Missouri
- Mercy Hospital Saint Louis - St Louis
Texas
- M D Anderson Cancer Center - Houston
Wisconsin
- Medical College of Wisconsin - Milwaukee
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 63 participants |
| Start Date | 2006-08-29 |
| Est. Completion | 2024-12-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00381641
The ClinicalTrials.gov registry entry for NCT00381641 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 63 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 35-participant average among 3 other Recurrent Thyroid Gland Carcinoma trials with a reported enrollment target (80% higher). The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 10 conditions, with Recurrent Thyroid Gland Carcinoma appearing as the primary indexed condition, and to 4 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT00381641 reports 17 study locations spanning 7 distinct geographic areas - top geographies include Illinois, Indiana, Michigan.
Frequently Asked Questions
What is clinical trial NCT00381641 about?
NCT00381641 is a clinical study titled "Sunitinib Malate in Treating Patients With Thyroid Cancer That Did Not Respond to Iodine I 131 and Cannot Be Removed by Surgery". This phase II trial studies how well sunitinib malate works in treating patients with thyroid cancer that did not respond to iodine I 131 (radioactive iodine) and cannot be removed by surgery. Sunitinib malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth ...
What is the current status of trial NCT00381641?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 63 participants. The study started on 2006-08-29. Estimated completion is 2024-12-10.
What conditions does trial NCT00381641 study?
This clinical trial studies the following conditions: Recurrent Thyroid Gland Carcinoma, Refractory Thyroid Gland Carcinoma, Differentiated Thyroid Gland Carcinoma, Stage IV Thyroid Gland Follicular Carcinoma AJCC v7, Stage IV Thyroid Gland Papillary Carcinoma AJCC v7.
What interventions are being tested in trial NCT00381641?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Sunitinib (DRUG), Pharmacogenomic Study (OTHER), Sunitinib Malate (DRUG).
Who is sponsoring clinical trial NCT00381641?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00381641 being conducted?
This trial has 17 study locations across Illinois, Indiana, Maryland, Michigan, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Recurrent Thyroid Gland Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Selpercatinib Before Surgery for the Treatment of RET-Altered Thyroid Cancer
ACTIVE NOT RECRUITING · Phase 2
-
Trametinib in Increasing Tumoral Iodine Incorporation in Patients With Recurrent or Metastatic Thyroid Cancer
ACTIVE NOT RECRUITING · Phase 2
-
Aflibercept in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy
COMPLETED · Phase 2
Explore more on PlainTrial
Recurrent Thyroid Gland Carcinoma
All registered trials for this condition
Refractory Thyroid Gland Carcinoma
All registered trials for this condition
Illinois
All trials with a study site in Illinois
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.